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Summary Niosomes are multilamellar vesicles formed from nonionic surfactants of the alkyl or dialkyl
polyglycerol ether class and cholesterol. Adriamycin has been trapped within vesicles prepared from a
monoalkyl triglycerol ether and its activity compared with adriamycin solution in human lung tumour cells
grown in monolayer and spheroid culture and in tumour xenografted nude mice. The activity of the
encapsulated adriamycin in vitro is maintained with similar clonogenic survival curves following treatment of
monolayers and identical growth delays following spheroid exposure. The pharmacokinetics of adriamycin are
altered in vivo in human lung tumour-bearing nude mice, when it is administered in niosomal form. There is
prolonged release of drug from the plasma compartment with significantly lower peak levels; lower peak
cardiac adriamycin concentrations with a shorter tissue half-life and decreased cardiac AUC and a greater
degree of hepatic metabolism to inactive 7-deoxyaglycones. The tumour peak drug level and AUC was similar
irrespective of the mode of administration of adriamycin. The growth delay (i.e. the time taken for the
tumour volume to double) was significantly longer for adriamycin (15 days) and niosomal adriamycin (11
days) than for control (5.8 days). It is possible that the therapeutic ratio of adriamycin could be enhanced by
administration in niosomal form.
Numerous attempts have been made to enhance the selec-
tivity of antineoplastic agents by linking them to a carrier
moiety. Human albumin in microspherical form (Florence et
al., 1988), macroaggregated protein (Szeberke et al., 1972),
monoclonal antibodies (Seta et al., 1982), DNA-anthra-
cycline complexes (Deprez-De Campaneere et al., 1979),
drug-hormone conjugates (Kaneko et al., 1981) and encapsu-
lation of the cytotoxic agents in liposomes (Gregoriadis,
1976; Rahman et al., 1982) are examples. There is no doubt
that in most cases the pharmacokinetics of the anticancer
drug are altered, sometimes favourably, with a resultant
decrement in toxicity. However, a number of problems
remain to be overcome to provide a clinically useful carrier
system, which include questions of (a) the specificity of the
carrier for tumour cells in vivo, (b) the stability of the carrier
complex in vivo, (c) the release of the active agent at the
target site, (d) non-specific uptake of exogenous material by
the reticuloendothelial systems (Poste, 1983) and (e) adverse
immunological reactions to the exogenous carrier.
A number of studies have demonstrated enhanced cytotox-
icity of liposome-encapsulated drugs in vitro (Kimelberg &
Mayhew, 1978). It has been proposed that this effect is
mediated via increased cellular drug uptake by a fusional or
endocytic process. However, there is controversy over the
ability of liposomes to diffuse from the vascular compart-
ment to the tumour interstitium or whether they would be
phagocytosed by cells of the reticuloendothelial system.
There is in vivo evidence, however, that administration of
liposomes to tumour bearing rodents decreases adriamycin
associated cardiac toxicity without loss of therapeutic effect
(Forssen & Tokes, 1983; Olsen et al., 1982). A preliminary
report of a phase I clinical study with liposome-associated
adriamycin indicated that liposome administration is feasible
and has potential advantages over free adriamycin with
regard to some of its immediate toxic side effects (Gabizon
et al., 1986).
Niosomes are multilamellar vesicles formed from non-ionic
surfactants of the alkyl or dialkyl polyglycerol ether class
and cholesterol. Earlier studies, in association with L'Oreal
have shown that, in general, niosomes have properties as
potential drug carriers similar to liposomes. The admini-
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stration of methotrexate to mice in niosomal form (Azmin et
al., 1985; Azmin et al., 1986) altered both the distribution
and metabolism of the drug. More recent work with adria-
mycin (Florence et al., 1988) has also indicated that both
organ distribution and metabolic patterns are changed by
administration of the drug niosomes. The methods of pre-
paration and pharmaceutical properties of niosomes have
been reported in detail in previous papers (Baillie et al.,
1985) and these preparations are used here.
In this paper the effect of niosomal encapsulation on the
pharmacokinetics and activity of adriamycin in human lung
tumour cells grown in monolayer, spheroids and nude mice
xenografts is reported.
Materials and methods
Preparation and c-haracterisation of niosomes
Niosomes were prepared by the hand-shaking and ether-
injection techniques which have been described previously
(Baillie et al., 1985).
Hand shaking technique One hundred and fifty ,umol of
50:50 surfactant 1-cholesterol mixture was dissolved in
diethylether (10ml) in a 50ml round-bottomed flask, and the
ether evaporated on a rotary evaporator (Buchli) at 40°C
under reduced pressure. The dried film was hydrated with
water or with 5 mgml - I adriamycin (50ml) at 50'C, for
15min, with gentle agitation. Niosomes prepared in this way
were 987+ 123 nm in diameter, as determined by photon
correlation spectroscopy.
FORMULA OF SURFACTANT I
C16 H33 (OCH2CH)n OH
CH2OH
WHERE n(AVERAGE)=3
Ether injection technique One hundred and fifty ,umol of
50:50 surfactant I-cholesterol mixture was dissolved in
diethylether (20ml) and injected slowly (0.25 ml min-1)
through a 14-gauge needle into water or aqueous solutions
of drug (20mM, 5ml) maintained at 60°C. After injection of
solvent the system was maintained at 60"C for I h to ensure
complete evaporation.
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Separation offree and entrapped adriamycin
Each niosome sample was suspended in a final volume of
approximately 20ml phosphate buffered saline (PBS)
(pH 7.2) and centrifuged (7,000g, 20°C, 30min). Superna-
tants were discarded and the pellets washed three times with
buffer and resuspended in PBS.
Estimation of entrapped adriamycin
The niosome suspension (5ml) was adjusted to pH 5 to
ionise the adriamycin, shaken with chloroform (10ml, 30sec)
in a 50ml separatory funnel, and after 5min the two phases
were separated. The upper, cloudy, aqueous phase contained
adriamycin and the lower chloroform layer surfactant. The
aqueous phase was clarified by gentle addition of double
distilled water (5ml) then collected and adriamycin concen-
tration analysed directly by an HPLC method.
The chloroform layer was evaporated to dryness, avoiding
heat, and was reconstituted in methanol (1 ml) prior to
immediate analysis. It was therefore possible to derive the
amount of adriamycin entrapped by the niosomes (-70%).
The stability of niosome encapsulated adriamycin and drug
release rates have been estimated for niosomes suspended in
serum and PBS and prolonged release has been demon-
strated (Baillie et al., 1985).
Murine pharmacokinetic studies
WIL, a human squamous lung tumour xenograft (Merry et
al., 1988) was serially passaged in 100mg fragments into
nude mice bred from the Department's colony. The tumour
fragments were inserted into a surgically created subcuta-
neous pouch on the right flank of ether anaesthetised mice.
The wound was closed with surgical clips, which were
removed seven days later. The mice were housed in a sterile
environment and received food and water ad libitum.
Approximately 3 weeks after initial transplantation, the flank
tumours were approximately lcm in diameter and easily
palpable. Adriamycin solution or niosome encapsulated
adriamycin was administered intravenously via the tail vein
in a dose of l0mgkg-1 in a volume of 0.1-0.2ml.
The mice were sacrificed by exsanguination under light
ether anaesthesia at specified time points thereafter (30min,
1 h, 2h, 4h, 12h, 24h and 48h). Four mice were used per
time point. Blood samples (1-2ml per mouse) were collected
into lithium heparin tubes, centrifuged (2,000rpm for 5min)
and the plasma separated and stored at -20°C until analy-
sis. The liver, kidneys, heart and tumour were dissected out,
washed once in ice cold PBS and blotted dry. Individual
tissues were then frozen rapidly in liquid nitrogen and stored
at -20°C until analysis.
Drug analysis
Adriamycin was extracted from the tissues using a silver
nitrate technique and measured by a sensitive and specific
HPLC assay (Cummings et al., 1984). The inter-assay and
intra-assay coefficients of variation were - 10%, and the
sensitivity 5 ngml- 1.
Mathematical analysis
Plasma drug levels were fitted to a 2 compartment open
model by the technique of least squares based on the
Marquhardt algorithm using an 'in house' programme. It
was therefore possible to calculate drug clearance and
volume of distribution (central and peripheral compart-
ments) from the microscopic constants. Tissue drug levels are
expressed as Mg drugg-1 of tissue and the area under the
concentration-time curves (AUC) was calculated by the
trapezoidal rule. Statistical comparisons were made by Stu-
dent's t-test with Bonferroni correction where appropriate.
Tumour growth delay in vivo
WIL, the squamous lung tumour xenograft used in the
pharmacokinetic studies, was serially passaged in 100mg
fragments into nude mice bred in our laboratory as des-
cribed above. When the flank tumours were 1Icm in
diameter and easily palpable, three groups of tumour bearing
mice (10 mice in each group) were treated with: free
adriamycin 7.5mgkg-1, an equimolar dose of niosomal
adriamycin and normal saline as control. Thereafter the
tumour volume was measured 3 times per week for 3 weeks.
Volume was assessed by measuring the two largest diameters
with specially adapted calipers.
Cell culture
The L-DAN cell line was derived from a patient with
squamous lung cancer (Merry et al., 1987). The cells were
maintained as a monolayer in exponential growth in Hams
F10/DMEM (50:50) with 8mM NaHCO3 supplemented
with foetal calf serum. The cells have a doubling time of
28+4h and a plating efficiency of -30%. The cells were
tested regularly to ensure that cultures remained mycoplasma
free. The monolayers were disaggregated enzymatically with
0.25% trypsin (Gibco Ltd) in PBS and resultant cell suspen-
sion (105 cellsml-1) used to provide cells for initiation of
tumour spheroids using the 'agar underlay' static method
(Yuhas et al., 1977).
During growth experiments, the medium was changed
weekly and spheroid size was monitored by twice weekly
measurement of the cross-sectional areas of individual spher-
oids using a 'Micromeasurements' image analysis system
coupled via a television camera to an inverted optical
microscope (Twentyman, 1982). These area measurements
were subsequently converted to volumes, assuming spherical
geometry.
Conditions ofdrug exposure and determination of cell survival
L-DAN monolayers (_ 8 x 105 cells) and spheroids were
exposed to free adriamycin, or niosomal adriamycin over a
range of concentrations (0.1-20 igml -1) for 1 h. After treat-
ment, the monolayer cells were harvested with 0.25% trypsin
in PBS, centrifuged and washed with ice cold medium. The
cells were then diluted in medium and seeded at levels of
200-1,000 cells ml-' in 5cm Petri dishes. The plates were
incubated for 12 days in an atmosphere of air plus 2% CO2.
The colonies were then fixed and stained with methylene
blue and colonies of more than 40 cells were counted. Three
replicate plates were used per experiment and each experi-
ment was repeated three times. Following the usual conven-
tion, the cloning efficiency of the untreated cells was
normalised to 100%, and the cloning efficiency of the treated
cells was expressed as a percentage of control survival.
Spheroids from two flasks were pooled and a number of
glass universal tubes were prepared, each containing two to
three hundred spheroids with a mean diameter of 350pm.
The spheroids were treated with similar drug concentrations
and durations of exposure as used in monolayer at 37°C
with intermittent agitation. At the end of this period the
spheroids were allowed to sediment, the drug containing
medium was removed and the spheroids washed with fresh,
ice cold medium.
A Pasteur pipette was used to transfer treated spheroids to
agar coated wells on a plastic tissue culture 24 well multidish
with 1 spheroid per well in 1 ml of medium. Twenty-four
spheroids were taken from each treatment group and area
measurements were made twice weekly as described. It was
thus possible to measure treatment-induced growth effects.
Results
Monolayer clonogenic survival
The survival curves are shown in Figure 1. There is no
difference in clonogenic cell kill between systems exposed to
adriamycin-loaded niosomes and free adriamycin, the
respective ID90s being 2.1 ggml-1 and 2.2jgml-1.434 D.J. KERR et al.
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Figure 1 Clonogenic cell survival curves for monolayers of L-
DAN following treatment with adriamycin (0) and niosomal
adriamycin (0) for 1 h. There were three replicate plates per
drug exposure and the experiment was repeated three times. The
vertical bars denote 1 s.d. of % survival.
Spheroid growth
We have previously published growth curves from typical
spheroid experiments (Kerr et al., 1986) and have therefore
presented the growth data in tabular form (Table I). Spher-
oid growth is similar at each drug concentration whether the
drug is free or entrapped in niosomes.
Tumour growth delay in vivo
The percentage increase in tumour weight (relative to pre-
treatment values) has been plotted against time for each of
the three treatment groups in Figure 2. Tumour growth in
the control group increased exponentially. The growth delay
(i.e., the time taken for the tumour weight to double) was
longer for free adriamycin (15 days) than for control (5.8
days) with niosomal adriamycin producing an intermediate
growth delay of 11 days. Tumour weights were, however,
not statistically different comparing free adriamycin vs. nio-
somes, but both the adriamycin treated groups tended to be
significantly smaller than controls (P<0.05) (Table II).
Table I Spheroid growth in response to treatment with free and
niosome bound adriamycin. There were -20 spheroids per point
and the experiments were repeated twice.
Median spheroid growth (days)a
Drug Free adriamycin Niosome-adriamycin
concentration (95% confidence (95% confidence
(ugml-1) limits) limits)
0 (control) 8.1 (6.3-8.9) 7.6 (6.5-8.2)
1 11.5 (10.0-14.2) 12 (11.1-12.4)
5 13.1 (12.0-14.9) 12.9 (10.8-13.7)
10 17.3 (15.4-18.3) 17.2 (15.1-18.0)
20 17.4 (14.5-19.2) 18.1 (17.2-18.8)
aGrowth period is defined as the time taken to reach 10 x original
volume.
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Figure 2 The % increase in tumour weight relative to pretreat-
ment values following treatment with adriamycin (7.5mgkg 1,
*), niosomal adriamycin (7.5mgkg-1, El) and normal saline
(0) as control. The vertical bars denote 1 s.d. of % increase in
tumour weight.
Pharmacokinetics
Peak drug levels and tissue AUCs are outlined in Table III.
The plasma concentration-time curve is shown in Figure 3.
Peak levels of free adriamycin were significantly higher than
with niosomal adriamycin. Niosomal adriamycin levels were
Table II The percentage increase in tumour weight (taking mean
pretreatment weights as 100%) with time, following treatment with
free adriamycin (7.5mgkg-1, i.v.) niosome encapsulated adriamycin
(7.5mgkg-1, i.v.), or 0.9% saline (0.1 ml, i.v.).
% Increase in tumour weight
Day Control Free adriamycin Niosome-adriamycin
0 100 100 100
2 135+9 100+10a,d 130+6
4 163+8 142+7a1d45+l11ad
7 232+27 163+19ab 177+8
9 242+18 143+36a,b 186+13a,d
11 262+41 160+29ab 204+23ad
15 354+11 203+21a,c 216+18a,c
17 456+26 250+18a.c 265 +24a.c
Student's t-test values: aNS comparing free vs. niosomes; bp<o.05
comparing free vs. control; CP<0.01 comparing free and niosome vs.
control; dNS comparing free and niosome vs. control.
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Figure 3 Plasma concentration-time curve for adriamycin
following administration as free solution (0) or in niosomal
from (0). The vertical bars denote 1 s.d. of drug concentration.
*=P<0.05, comparing concentrations for free and niosomal
adriamycin.
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maintained at roughly constant levels for the first 4h
following bolus injection and declined monoexponentially
thereafter.
Plasma adriamycin levels were significantly higher between
4-12h following administration of adriamycin in niosomes,
and this was reflected in a higher mean AUC. As it is
impossible to take multiple plasma samples from single mice,
it is not possible statistically to compare AUCs as this
parameter is derived from single samples from multiple
animals. Nevertheless, the form of the plasma concentration
profiles differs. Adriamycin clearance (free solution=
0.51h-1; niosomes=0.381h-1), volume of distribution (free
solution = 5.7 1; niosomes = 1.1 1) and apparent terminal
plasma half lives (free solution=8 h; niosomes =2h) were
calculated. The high volume of distribution indicates exten-
sive tissue binding of adriamycin. It was not possible to
detect a second phase of decline in plasma drug concen-
tration for niosomal adriamycin, however, if plasma sam-
pling had been continued for a further 12-24h biphasic
decline in plasma levels may have become apparent.
Hepatic tissue levels of adriamycin were similar regardless
of the formulation. The AUCs, peak hepatic levels (Table
III) and issue half-lives (17h) for adriamycin were statis-
tically indistinguishable. The degree of hepatic metabolism of
drug was greater for niosome encapsulated adriamycin as
found by Rogerson et al. (1987) in related experiments
(Figure 4). Peak levels of the 7-deoxyaglycone of adria-
Table III Comparative total tissue and plasma contents of adria-
mycin following administration of free and niosome encapsulated
drug. Peak levels are expressed at Mgg - (pg ml - for plasma)+±
s.d. and the AUC as pgg 1 tissuexhour (pgmlP-.h for plasma).
Niosome encapsulated
Free adriamycin adriamycin
AUC AUC
Peak level (ughml-1) Peak level (pghml-1)
(Pgml-1) (0- ) (pgml-1) (0_ )
Plasma 0.1+0.01 0.4 0.075+O.OIa 0.53
Heart 11.7+0.10 110 5+0.27a 43.6
Kidney 24+1.8 295 11.3+1.2a 160
Liver 27.9+5.9 195 14.2+4.5 175
Tumour 4.7+0.6 30 6.9 +0.9a 41
aIndicates significant (P<0.05) differences in peak levels.
b
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mycinol are significantly higher (P<0.05) after niosome
treatment. The degree of hepatic metabolism can be defined
by the ratio:
[AUC adriamycin]/[AUC adriamycin
+AUC metabolites] x 100%
The metabolism ratio for niosomal adriamycin (85%) is
less than for free adriamycin (95%) despite similar AUCs for
parent drug, implying greater hepatic uptake and metabolism
for adriamycin encapsulated in niosomes.
Peak renal levels are significantly (P<0.05) higher after
free adriamycin. The renal AUC is also higher (Table III)
and the tissue half life rather shorter (20.6h vs. 36.4h) than
for niosomal adriamycin. There was a minor degree (<5%)
of metabolism of adriamycin to the deoxyaglycones of
parent drug and adriamycinol, which was similar for free
and niosomal drug.
Cardiac adriamycin concentrations were significantly and
consistently higher throughout the concentration time profile
(Figure 5) in the free adriamycin group. Peak level, AUC
and the terminal half life (36h vs. 10.8h) were elevated over
those values observed with the niosomes (Table III). There
was no significant intracardiac metabolism of adriamycin
with either preparation of the drug.
Intratumoural drug levels were similar with regard to
AUC (Table III). Peak concentration of adriamycin was
higher following niosomal treatment (p<0.05). The terminal
half life is apparently prolonged in mice treated with free
adriamycin. However, this accounts for only a small fraction
of the total AUC (<5%). No intratumoural metabolites
were detected.
Discussion
The cytotoxic activity of adriamycin is maintained in vitro
and in vivo despite encapsulation in niosomal vesicles. The
niosomes possibly interact with cells in vitro in several
different ways. Adsorption is likely to be a non-specific lipid-
surfactant interaction occurring at the cell surface. This
could allow locally high concentrations of drug to accumu-
late at the cell surface following drug diffusion out of the
niosomes, thus promoting cellular uptake of drug. Alterna-
tively, adsorption may lead to endocytic incorporation of the
niosomes and their contents into the cell. Following endo-
cytic uptake, the vesicles are presumably degraded within the
cell thus allowing the drug to diffuse to its site of action
within the nucleus.
Spheroid growth delay for niosomal adriamycin is vir-
tually the same as for free adriamycin. Although soluble
surfactants may increase cell permeability, it is difficult to
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Figure 4 Metabolites of adriamycin measured within the liver:
7-deoxyaglycone of adriamycin (0)
7-deoxyaglycone of adriamycinol (0)
following administration of free solution (A) or in niosomal form
(B). The vertical bars denote 1 s.d. of drug concentration.
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Figure 5 Cardiac tissue levels of adriamycin following admini-
stration as free solution (0) or in niosomal form (0). The
vertical bars denote 1 s.d. of drug concentration.
*=P<0.05, **=P<0.01, comparing concentrations for free
and niosomal adriamycin.
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envisage non-ionic surfactant niosomes disrupting spheroid
structure or diffusing intact into the spheroid, therefore
presumably enough adriamycin is taken up by the external
cell annulus to allow production of a concentration gradient
sufficiently large to match the growth delay associated with
free adriamycin.
Encapsulation of adriamycin in niosome vesicles alters the
pharmacokinetics and disposition of the drug in tumour
xenograft bearing nude mice. The significant differences,
relative to administration of adriamycin solution, are as
follows; prolonged release of drug from the plasma compart-
ment with lower peak levels; lower peak cardiac levels of
adriamycin with a shorter tissue half life and decreased
cardiac AUC; a greater degree of hepatic metabolism to
inactive 7-deoxyaglycones.
Cardiac levels of adriamycin are significantly lower with
the niosomal drug preparation. Peak plasma levels of adria-
mycin are thought to be directly correlated with the develop-
ment of cardiomyopathy and this concept underlay the use
of prolonged infusion of adriamycin in chemotherapeutic
regimens in order to decrease peak drug levels and hence the
chance of cardiac damage (Unverferth et al., 1982). The
niosomes decreased peak plasma and cardiac adriamycin
concentrations and total cardiac drug exposure (as assessed
by the lowered tissue AUC). Although the cardiac toxicity of
the niosomes relative to equimolar doses of adriamycin has
not been formally assessed, it is possible, on pharmacokinetic
grounds, that the niosomes will be relatively cardio-
protective.
On the basis of tumour drug exposure (tumour adriamycin
AUC), one would predict that free and niosome bound
adriamycin would have similar cytotoxic efficacy. This
appears to be the case, with similar tumour volume doubling
times in the treated groups (Table II). In view of the finding
of indistinguishable antitumour activity and the alluded
assoc-)ition between intracardiac adriamycin levels and the
subsequent development of cardiomyopathy, then niosome
encapsulated adriamycin would seem to have a higher thera-
peutic ratio than free adriamycin.
Although the niosomes are chemically and physio-
chemically distinct from liposomes structurally they bear
many similarities, and the results reported in this study are
qualitatively similar to those in previously executed studies
employing liposomes as the carrier vehicle for adriamycin
(Gregoriadis, 1976; Kimelberg & Mayhew, 1978; Forssen &
Tokes, 1983; Olsen et al., 1982).
It can be concluded that niosome encapsulated adriamycin
has a different tissue distribution from that of free adriamy-
cin, with the predominant effect being lowered cardiac drug
concentrations. It is possible, as total dose limitation in
antineoplastic therapy is related to development of cardio-
myopathy, that even a modest reduction in cardiotoxicity
could enable an increase in the total dose of adriamycin
administered for a reduction in the likelihood of toxicity.
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